This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Dihydroergocryptine is a dopamine agonist indicated in the treatment of cerebrovascular diseases and atherosclerosis.
- Generic Name
- Dihydroergocryptine
- DrugBank Accession Number
- DB13385
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of Dihydroergocryptine can be increased when it is combined with Abametapir. Abatacept The metabolism of Dihydroergocryptine can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Dihydroergocryptine. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Dihydroergocryptine. Acebutolol Acebutolol may increase the vasoconstricting activities of Dihydroergocryptine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Dihydroergocryptine mesylate 5AAV003TAQ Not Available Not applicable - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image TOTERJİN DAMLA, 50 CC Dihydroergocryptine (33 %) + Dihydroergocristine (33 %) + Ergoloid mesylate (33 %) Solution / drops Oral BİLİM İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 2018-08-16 Turkey 
นาลีน Dihydroergocryptine mesylate (333 MCG) + Dihydroergocornine mesylate (333 MCG) + Dihydroergocristine mesylate (333 MCG) Tablet บริษัท สหแพทย์เภสัช จำกัด 1985-04-02 Not applicable Thailand 
เฮลคอน Dihydroergocryptine mesylate (333 MCG) + Dihydroergocornine mesylate (333 MCG) + Dihydroergocristine mesylate (333 MCG) Tablet บริษัท โปลิฟาร์ม จำกัด จำกัด 1985-06-15 Not applicable Thailand
Categories
- ATC Codes
- N04BC03 — Dihydroergocryptine mesylate
- Drug Categories
- Agents that produce hypertension
- Alkaloids
- Anti-Parkinson Drugs
- Cardiovascular Agents
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates (strength unknown)
- Cytochrome P-450 Substrates
- Dopamine Agents
- Dopamine Agonists
- Ergot Alkaloids and Derivatives
- Ergot-derivative Dopamine Receptor Agonists
- Ergotamines
- Heterocyclic Compounds, Fused-Ring
- Nervous System
- Neurotransmitter Agents
- Vasodilating Agents
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 67V3FSL2GL
- CAS number
- Not Available
References
- General References
- FDA Thailand: NALINE (dihydroergocornine, dihydroergocristine, dihydroergocryptine) oral tablets [Link]
- External Links
- 3417
- Wikipedia
- Dihydroergocryptine
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Capsule Solution / drops Oral Solution / drops Oral Tablet - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- de Mey C, Althaus M, Ezan E, Retzow A: Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans. Clin Pharmacol Ther. 2001 Aug;70(2):142-8. doi: 10.1067/mcp.2001.117286. [Article]
- Wooltorton E: Risk of stroke, gangrene from ergot drug interactions. CMAJ. 2003 Apr 15;168(8):1015. [Article]
Drug created at June 23, 2017 20:41 / Updated at June 02, 2021 20:04